Evidence map›Paper›PMID 33611618›Full record

ArticleCurrent microbiology2021

Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms.

Juan Zhu, Pengfei She, Juhua Fu, Canhui Peng, Yong Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Antimicrobial Resistance: The Answers.British journal of biomedical science · 2026
    Review
  2. Article
  3. Antimicrobial and Antibiofilm Effects of Bithionol againstAntibiotics (Basel, Switzerland) · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Juan ZhuDepartment of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Changsha, 410013, Hunan, People's Republic of China.
Pengfei SheDepartment of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Changsha, 410013, Hunan, People's Republic of China. shepengfei_xy@csu.edu.cn.
Juhua FuDepartment of Human Resources, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China.
Canhui PengDepartment of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Changsha, 410013, Hunan, People's Republic of China.
Yong WuDepartment of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Changsha, 410013, Hunan, People's Republic of China. wuyong_zn@csu.edu.cn.
Third Xiangya Hospital · CNCentral South University · CN

Funding

Natural Science Foundation of Hunan Province 2020JJ5877Scientific research project of Hunan Health Commission 20201453
6 · The paper itself

Abstract

Staphylococcus epidermidis is a common cause of nosocomial infections, and readily adheres to medical apparatus to form biofilms consisting of highly resistant persister cells. Owing to the refractory infections caused by S. epidermidis biofilms and persisters in immunosuppressed patients, it is crucial to develop new antimicrobials. In the present study, we analyzed the antimicrobial effects of the thrombopoietin receptor agonist eltrombopag (EP) against S. epidermidis planktonic cells, biofilms, and persister cells. EP was significantly toxic to S. epidermidis with the minimal inhibitory concentration of 8 μg/ml, and effectively inhibited the biofilms and persisters in a strain-dependent manner. In addition, EP was only mildly toxic to mammalian cells after 12 to 24 h treatment. It also partially synergized with vancomycin against S. epidermidis, which enhanced its antimicrobial effects and reduced its toxicity to mammalian cells. Taken together, EP is a potential antibiotic for treating refractory infections caused by S. epidermidis.

Indexed as

Pharmaceutical PreparationsStaphylococcus epidermidisAnimalsAnti-Bacterial AgentsBenzoatesBiofilmsDrug RepositioningHumansHydrazinesMicrobial Sensitivity TestsPyrazolesAnti-Bacterial AgentsBenzoateseltrombopagHydrazinesPharmaceutical PreparationsPyrazoles

Identifiers

PMID33611618
OpenAlexW3129510743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.